Shasqi Advances SQ3370 to Phase 2 in Solid Tumors

Corporate Breaking News

Home : Shasqi Advances SQ3370 to Phase 2 in Solid Tumors

Sep 12 2022	Shasqi Advances SQ3370 to Phase 2 in Solid Tumors
Shasqi's lead asset, SQ3370 is designed to activate doxorubicin at the tumor site and established click chemistry in humans Phase 1 data presented at ESMO Congress 2022 show SQ3370 is well-tolerated among patients receiving up to approximately 12 times the standard dose of doxorubicin...


Source:https://www.prnewswire.com:443/news-releases/shasqi-advances-sq3370-to-phase-2-in-solid-tumors-301621697.html

Related News
» Compliancy Group is the American Psychological Association's Preferred Provider for HIPAA Compliance Solutions » Broadridge and Euronext Collaborate to Transform the Proxy Voting Lifecycle in Denmark